Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype

Laura Z. Vanags, Joanne T.M. Tan, Keyvan K. Galougahi, Andreas Schaefer, Steven G. Wise, Andrew Murphy, Ziad A. Ali, Christina A. Bursill

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosis and platelet activation, and enhances endothelialization. These findings have therapeutic implications for improving stent biocompatibility.

Original languageEnglish
Pages (from-to)200-209
Number of pages10
JournalJACC: Basic to Translational Science
Volume3
Issue number2
DOIs
Publication statusPublished or Issued - Apr 2018
Externally publishedYes

Keywords

  • apolipoprotein A-I
  • endothelialization
  • neointimal hyperplasia
  • platelet activation
  • stent biocompatibility

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this